Conference Correspondent

The role of the oncology pharmacist in promoting oral adherence for the oncology patient is discussed.

Latest Developments in Short-Acting Granulocyte Colony-Stimulating Factor (G-CSF) Treatment Options: The First FDA-Approved Biosimilar, Zarxio® (filgrastim-sndz)

Biosimilarity between Zarxio and Neupogen is proven through PIONEER study results.

Updated Analysis of the Efficacy of Daratumumab Combination Therapy in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy

Heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) derived significant benefit from a combination of daratumumab, dexamethasone, and bortezomib. These data continue to support the addition of daratumumab to a standard-of-care regimen in RRMM.

Use of Montelukast to Reduce Infusion Reactions in Patients with Relapsed or Refractory Multiple Myeloma

Administration of the asthma medication montelukast more than 30 minutes before infusion of daratumumab can drastically reduce infusion-related reactions in patients with multiple myeloma.

Efficacy of Daratumumab in Combination for Relapsed/Refractory Multiple Myeloma, Based on Previous Treatment Exposure

In a subgroup analysis of the POLLUX trial, daratumumab plus lenalidomide/dexamethasone was associated with superior progression-free survival and response rates versus lenalidomide/dexamethasone alone among patients who were previously treated with bortezomib or who were bortezomib-refractory or lenalidomide-naïve.

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma in Patients with 1 to 3 Prior Lines of Therapy

Clinical outcomes were better when daratumumab was added to a regimen of patients with relapsed/refractory multiple myeloma who received prior therapy.

Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies

Pharmacokinetic analysis of daratumumab as part of combination regimens identified no clinical or demographic characteristics that altered exposure and activity of the monoclonal antibody. The findings support the body-weight–based dosing of 16 mg/kg.

Real-World Benefit Shown for Daratumumab Monotherapy versus Physician’s Choice

Data from a “real-world” historical cohort of heavily pretreated patients in the Czech Republic confirmed the benefits shown in clinical trials of single-agent daratumumab compared with treatment by physician’s choice.

Real-World Trends in Treatment Use, Healthcare Costs, and Overall Survival Among Patients with Multiple Myeloma

As out-of-pocket costs continue to rise, patients and healthcare stakeholders are increasingly concerned about the relative value of different treatment options. This claims-based analysis assesses trends in novel therapy use, total healthcare costs, and survival outcomes among newly diagnosed multiple myeloma patients in the United States since 2000.

Retreatment with Daratumumab Among Refractory Patients with Multiple Myeloma

Unmet treatment needs remain in multiple myeloma, particularly among patients with relapsed/refractory disease who have received multiple lines of therapy. This study evaluates a potential salvage approach of daratumumab-based retreatment in patients refractory to daratumumab and/or pomalidomide.

Page 8 of 28
Results 71 - 80 of 273

Conference Correspondent

I'd like to receive: